Trial Profile
Mechanistic Studies of Teriflunomide in Relapsing Remitting Multiple Sclerosis: Regulatory B Lymphocytes as Central Mediators of the Therapeutic Effects of Teriflunomide in MS
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2022
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 23 Dec 2022 Status changed from active, no longer recruiting to completed.
- 27 Jul 2022 Planned End Date changed from 1 Aug 2022 to 1 Dec 2022.
- 27 Jul 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Dec 2022.